<DOC>
	<DOC>NCT02732210</DOC>
	<brief_summary>The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.</brief_summary>
	<brief_title>Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description>The study was a multi-center, single-arm, prospective, non-interventional observational study in postmenopausal women with osteoporosis who had been treated with Prolia® for osteoporosis in routine clinical practice.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Enrollment within 4 weeks following administration of the first Prolia® (denosumab 60 mg) injection Received Prolia® subcutaneously for treatment of osteoporosis consistent with local (US/Canada) product label Subject or subject's legally acceptable representative has provided informed consent. Participation in ongoing or previous denosumab clinical trials Currently enrolled in another investigational device or drug study, or less than 6 months since ending another investigational device or drug study(s), or receiving other investigational agent(s) Contraindicated for treatment with Prolia® according to the approved applicable local product label (US/Canada) Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>